Disclosed, not promised — so here is the year's deal map drawn only from records you can verify. Five themes carried therapeutics dealmaking in 2026, and each traces to specific IP this desk has covered. First, the incretin metabolic franchise: Lilly's GIP/GLP-1 method-of-use grants (US12453758B2) and Novo Nordisk's GLP-1 derivative grants (US10392428B2) anchor the most-debated valuations in the sector, with tri-agonist applications (US20260151493A1) marking where it goes next.
Second, gene editing — the deal-dense frontier. CRISPR Therapeutics' target-specific grants (US12644123B2) and Editas' edited-stem-cell application (US20260159855A1) sit downstream of foundational enzyme IP from research institutes like the Broad (US12644111B2). The clean ownership story and the foundational overhang are both real, and both priced into the year's gene-editing transactions.
Third, mRNA delivery — the quiet royalty tier. Ionizable-lipid grants such as the University of Pennsylvania's (US12576040B2) sit upstream of many mRNA products' economics, the layer a deal teardown skips at its peril. Fourth, oncology antibodies: validated targets like BCMA keep generating licensing flow, with specific binders (US12643952B2) as the bankable assets under the term sheets.
Fifth, precision diagnostics — the market-sizing layer. Detection grants like Foundation Medicine's NTRK-fusion patent (US12649952B2) gate the addressable markets that targeted-drug deals are valued against. And underneath the durable incumbents, franchise IP like Vertex's CFTR-modulator grants (US10022352B2) funds the diversification bets that become next year's deals.
The editor's close: every theme on this map is anchored in a document you can open and read, not a narrative you have to trust. That is the whole standard. When the deal flow and the patent record agree — and across these five themes in 2026, they do — you are looking at substance. When they diverge, you are looking at a story. A deals desk's job is to know which one is on the page in front of it.